Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials

Tyring, Stephen K.; Díaz‐Mitoma, Francisco; Shafran, Stephen D.; Locke, Leslie Ann; Sacks, Stephen L.; Young, Clarence L.

doi:10.1007/s10227-002-0141-2

Cited by 14 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…65 A larger study evaluating 250 mg of famciclovir twice a day demonstrated that 70% of those receiving the drug were recurrence free for 1 year, compared with only 20% of patients in the placebo group. 82 Various regimens of the drug (125 mg 3 times a day, 250 mg 3 times a day, and 250 mg twice a day) significantly increase time to first recurrence and percentage of patients remaining recurrence free for 1 year. Results attained with 250 mg of famciclovir twice a day or 3 times a day have been similar.…”

Section: Cst In Genital Herpes Simplexmentioning

confidence: 99%

The Treatment of Herpes Simplex Infections<subtitle>An Evidence-Based Review</subtitle>

Cernik¹

2008

Arch Intern Med

171

View full text Add to dashboard Cite

enital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research;(3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections. The physician must first choose an approach to treatment (ie, intermittent episodic therapy, intermittent suppressive therapy, or chronic suppressive therapy) based on defined clinical characteristics and patient preference. Then, an evidence-based dosing regimen must be selected. In this review, data from all sources are tabulated to provide a handy clinical reference.

show abstract

Section: Cst In Genital Herpes Simplexmentioning

confidence: 99%

The Treatment of Herpes Simplex Infections<subtitle>An Evidence-Based Review</subtitle>

Cernik¹

2008

Arch Intern Med

171

View full text Add to dashboard Cite

show abstract

“…Suppressive therapy can reduce the frequency of symptomatic recurrences and asymptomatic viral shedding. 1,7 Famciclovir (Famvir ® , Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), a prodrug of the antiviral agent penciclovir, has been shown to be effective as both episodic [8][9][10] and suppressive [11][12][13] treatment of recurrent genital herpes.…”

Section: Introductionmentioning

confidence: 99%

Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial

Bartlett¹,

Tyring²,

Fife³

et al. 2008

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

“…Also, Tyring et al. demonstrated famciclovir 250 mg twice daily to be an effective, well‐tolerated regimen for suppression of genital herpes among individuals with multiple recurrences (39).…”

Section: Introductionmentioning

confidence: 99%

Therapy of other viral infections: herpes to hepatitis

Chakrabarty¹,

Beutner²

2004

Dermatol Ther

View full text Add to dashboard Cite

Over the past several years, there has been an increase in knowledge pertaining to the diagnosis and management strategies for the herpes family (Types 1-8), the pox viruses, mumps, measles, rubella, and parvovirus B19 as well as the viral etiologies of hepatitis. Various antiviral treatments, such as nucleoside analogs and interferon therapy, have been available to reduce the signs and symptoms of these common viral infections. This article summarizes the preferred treatment strategies to be employed for each of the viruses for reducing severity, duration, recurrences (notably in the herpes family), transmission rates, as well as preventive alternatives. The majority of the therapeutic options attenuate the course of disease. Treatment decisions are driven by knowledge of the natural history and often are tailored to incorporate clinical circumstances for individual patients. Promotion of community awareness and the development of vaccines should be emphasized in the battle against these common viruses, particularly the herpes simplex viruses, the pox viruses, and hepatitis B.

show abstract

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials

Abstract: Oral famciclovir 250 mg twice daily is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences.

Cited by 14 publications

References 19 publications

The Treatment of Herpes Simplex Infections<subtitle>An Evidence-Based Review</subtitle>

The Treatment of Herpes Simplex Infections<subtitle>An Evidence-Based Review</subtitle>

Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial

Therapy of other viral infections: herpes to hepatitis

Contact Info

Product

Resources

About